TENORMIN Drug Patent Profile

✉ Email this page to a colleague

When do Tenormin patents expire, and what generic alternatives are available?

Tenormin is a drug marketed by Astrazeneca and Twi Pharms and is included in two NDAs.

The generic ingredient in TENORMIN is atenolol. There are thirty-four drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the atenolol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tenormin

A generic version of TENORMIN was approved as atenolol by TWI PHARMS on July 15^th, 1988.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for TENORMIN?
What are the global sales for TENORMIN?
What is Average Wholesale Price for TENORMIN?

Summary for TENORMIN

US Patents:	0
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	163
Clinical Trials:	16
Patent Applications:	5,013
Drug Prices:	Drug price information for TENORMIN
What excipients (inactive ingredients) are in TENORMIN?	TENORMIN excipients list
DailyMed Link:	TENORMIN at DailyMed

Drug patent expirations by year for TENORMIN

Recent Clinical Trials for TENORMIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Tennessee Medical Center	Early Phase 1
High Risk Obstetrical Consultants	Early Phase 1
University of Tennessee Graduate School of Medicine	Early Phase 1

See all TENORMIN clinical trials

Pharmacology for TENORMIN

Drug Class	beta-Adrenergic Blocker
Mechanism of Action	Adrenergic beta-Antagonists

US Patents and Regulatory Information for TENORMIN

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	TENORMIN	atenolol	INJECTABLE;INJECTION	019058-001	Sep 13, 1989		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Twi Pharms	TENORMIN	atenolol	TABLET;ORAL	018240-002	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Twi Pharms	TENORMIN	atenolol	TABLET;ORAL	018240-004	Apr 9, 1990	AB	RX	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Twi Pharms	TENORMIN	atenolol	TABLET;ORAL	018240-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for TENORMIN

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Twi Pharms	TENORMIN	atenolol	TABLET;ORAL	018240-004	Apr 9, 1990	⤷ Sign Up	⤷ Sign Up
Twi Pharms	TENORMIN	atenolol	TABLET;ORAL	018240-001	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
Twi Pharms	TENORMIN	atenolol	TABLET;ORAL	018240-001	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
Twi Pharms	TENORMIN	atenolol	TABLET;ORAL	018240-002	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for TENORMIN

See the table below for patents covering TENORMIN around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Belgium	746107		⤷ Sign Up
Yugoslavia	34280		⤷ Sign Up
Hungary	164914		⤷ Sign Up
United Kingdom	1392610		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for TENORMIN

Recent Clinical Trials for TENORMIN

Pharmacology for TENORMIN

Make Better Decisions: Try a trial or see plans & pricing